Pregnenolone-d₄-1

Cat. No.:	HY-B0151S2	2						
CAS No.:	61574-54-7							
Molecular Formula:	$C_{21}H_{28}D_4O_2$							
Molecular Weight:	320.5							
Target:	TRP Channe	el; Autopl	ohagy; Cannabinoid Receptor; Endogenous Metabolite					
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling; Autophagy; GPCR/G HO							
Storage:	Powder	-20°C	3 years					
		4°C	2 years					
	In solvent	-80°C	6 months					
		-20°C	1 month					

SOLVENT & SOLUBILITY

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.1201 mL	15.6006 mL	31.2013 mL
	5 mM	0.6240 mL	3.1201 mL	6.2402 mL
	10 mM	0.3120 mL	1.5601 mL	3.1201 mL

DIOLOGICALACITY					
Description	Pregnenolone-d ₄ -1 is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling- specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].				
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

REFERENCES



[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Vallée M, et al. Pregnenolone can protect the brain from cannabis intoxication. Science. 2014 Jan 3;343(6166):94-8.

[3]. Alan Shiels. TRPM3_miR-204: a complex locus for eye development and disease. Hum Genomics. 2020 Feb 18;14(1):7.

[4]. Ducharme N, et al. Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. Eur J Pharmacol. 2010 Sep 1;641(2-3):128-34.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA